10.28.13
EMD Serono, a subsidiary of Merck KGaA, and Open Monoclonal Technology, Inc. (OMT) have expanded their collaboration; EMD Serono will make an upfront payment to secure unlimited access to OMT’s OmniRat platform, as well as success-based development milestones and royalties. Financial details were not disclosed.
“The expansion of our collaboration with OMT is reflective of its strong quality and the significant progress we've made together over the last 15 months," said Dr. Annalisa Jenkins, executive vice president and head of Global R&D for Merck Serono, a biopharmaceutical division of Merck KGaA, Darmstadt, Germany. “This is a good example of our focus on exploring targeted partnerships with innovative companies such as OMT, with the goal of generating access to technologies that advance our capabilities in biotech development.”
Dr. Roland Buelow, founder and chief executive officer of OMT, said, "EMD Serono’s transition to unlimited platform access is evidence of their success with OmniRat on multiple therapeutic targets during the past 15 months. The expansion illustrates how OMT provides its partners with access to complementary platforms for discovery of superior antibodies against challenging targets in a cost-effective fashion.”
“The expansion of our collaboration with OMT is reflective of its strong quality and the significant progress we've made together over the last 15 months," said Dr. Annalisa Jenkins, executive vice president and head of Global R&D for Merck Serono, a biopharmaceutical division of Merck KGaA, Darmstadt, Germany. “This is a good example of our focus on exploring targeted partnerships with innovative companies such as OMT, with the goal of generating access to technologies that advance our capabilities in biotech development.”
Dr. Roland Buelow, founder and chief executive officer of OMT, said, "EMD Serono’s transition to unlimited platform access is evidence of their success with OmniRat on multiple therapeutic targets during the past 15 months. The expansion illustrates how OMT provides its partners with access to complementary platforms for discovery of superior antibodies against challenging targets in a cost-effective fashion.”